A comprehensive view of Home Use/Self-Care. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA approves AstraZeneca and Amgen’s Tezspire tezepelumab in a pre-filled, single-use pen for patients aged 12 and older with severe asthma; Tezspire is the only biologic approved for severe asthma with no phenotype for use at home or doctor’s office
Published: February 02, 2023 by AstraZeneca AB
Health Canada approves Apex Labs’ take home psilocybin clinical trial; study to evaluate efficacy, safety, tolerability of APEX-52, a microdose, oral synthetic psilocybin drug product to treat depression, anxiety in adults diagnosed with PTSD
Published: January 19, 2023 by Canada Newswire
AstraZeneca’s Tezspire in new pre-filled pen approved for self-administration in EU for severe asthma patients aged 12 years and older; FDA approval on self-administration from pre-filled pen expected in first half of 2023
Published: January 13, 2023 by Alliance News
UK-based health startup Daye completes £10M funding round, which will enable it to launch world's first tampon-based at-home microbiome screening kit to test for vaginal infections, such as thrush or bacterial vaginosis
Published: October 28, 2022 by Contify Life Science News
GlobalData predicts wearable technology sector to grow 24.6%/year between 2020-2024 to reach US$156B, driven by fitness trackers, as people sought to keep fit at home during pandemic; medical wearables can be used to detect heart rate, other vital signs
Published: October 24, 2022 by GlobalData Plc

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count